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Purpose: To identify cytokine-induced changes in the secretome of human retinal pigment epithelial (RPE) cells and their
potential implication in age-related macular degeneration pathogenesis.
Methods: Stable isotope labeling by amino in cell culture (SILAC) was used in combination with liquid chromatography
tandem mass spectrometry (LC-MS/MS) to measure differential protein secretion from tumor necrosis factor-α (TNF-α)
treated ARPE-19 versus untreated ARPE-19 cells. Typically, one set of cells was subcultured in a medium in which Arg
and Lys were replaced by 13C6-Arg and 15N2, 13C6-Lys while the other set of cells was grown in unlabeled medium. The
fully labeled cells were then treated with TNF-α, while unlabeled cells were left untreated. Spent media from both treated
and untreated cells were collected, mixed at 1:1 ratio, and processed for LC-MS/MS analysis. Labeled and unlabeled
peptide pairs were identified and their intensities were used to determine protein ratios in TNF-α treated cells versus
untreated cells. To validate the data, we performed a reverse experiment in which unlabeled cells were treated with TNF-
α while labeled cells were kept untreated.
Results: A total of 146 proteins were identified as putatively secreted proteins in the spent medium of ARPE-19 cells and
only six among these were differentially secreted following TNF-α treatment. Secretion of complement 3 and sulfhydryl
oxidase-1 was increased by twofold, fibronectin by 1.7 fold, plasminogen activator inhibitor 1 by 1.9 fold and syndecan-4
by 4.35 fold while secretion of trans-golgi network protein-2 was decreased by twofold.
Conclusions: TNF-α modulates secretion of specific proteins in ARPE-19 cells. These proteins are involved in pathways
relevant to AMD pathogenesis (e.g., extracellular matrix remodeling, complement pathway, and angiogenesis).
Age-related macular degeneration (AMD) is a leading
cause  of  blindness  in  elderly  individuals  [1].  AMD  is
characterized  by  extracellular  deposits  (e.g.,  drusen)  that
accumulate beneath the retinal pigment epithelium (RPE) and
along  Bruch’s  membrane  [2–4].  Previous  studies  have
established  a  strong  association  between  the  Tyr402His
variant in complement factor H (Y402H CFH) and the risk of
developing  AMD  [5–8].  More  recently,  a  variant  in  the
promoter region of the gene encoding for the serine protease
HtrA1 was found to be a second major risk factor for AMD
[9–11]. However, the mechanisms by which these single point
mutations  contribute  to  AMD  pathogenesis  (e.g.,  drusen
accumulation and choroidal neovascularization) are still not
well understood.
RPE cells have long been suspected to be a source for at
least some of the material that accumulates in drusen [2,12].
Our study of the secretome of human primary RPE cultures
clearly demonstrated that these cells can express and secrete
several  proteins  found  in  drusen  including  CFH  and
complement components [13]. RPE are highly specialized
epithelial  cells  that  maintain  integrity  of  the  blood-retina
barrier while performing vital functions such as phagocytosis
of the outer segment of photoreceptor cells, recycling of visual
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pigment,  and  transport  of  nutrients  to  the  photoreceptors
[14]. Hence, RPE cells are continuously exposed to oxidative
stress  and  proinflammatory  stimuli  that  may  disrupt  their
extracellular  environment  and  challenge  their  local
homeostasis.
The  presence  of  few  small  drusen  in  the  macula  of
individuals over age 40 is normal and usually not harmful.
However, an increase in number and size of these deposits is
a strong indication of a progressive AMD. Previous studies
have shown that drusen attract macrophages to the sub-RPE
space [15,16]. Activated macrophages are known to produce
tumor necrosis factor-α (TNF-α), a pleotropic cytokine, which
has  been  shown  to  stimulate  production  of  monocyte
chemotactic protein (MCP-1) by RPE cells thus recruiting
more macrophages to the vicinity of the sub-RPE space [17,
18]. Chronic exposure of RPE cells to cytokine may alter their
protein secretion pattern and increase the risk of complex
deposition. However, RPE cells express both soluble and cell
surface cytokine receptors as well as a variety of other factors,
thus giving them some degree of control to modulate the effect
of  cytokines  [19].  This  regulation  of  the  extracellular
environment  may  be  compromised  in  RPE  cells  carrying
AMD genetic risk variants (e.g., the Y402H CFH and the
HtrA1 promoter polymorphisms), leading to an accumulation
of extracellular deposits.
In  this  preliminary  study  we  decided  to  examine  the
overall effect of TNF-α on the regulation of protein secretion
by  RPE  cells  and  bring  insight  into  cytokine-induced
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2292alterations and their role in AMD pathogenesis. We used
ARPE-19 cells as a model to optimize the conditions for future
studies using human primary RPE cell culture.
Stable  isotope  labeling  by  amino  acid  in  cell  culture
(SILAC)  is  a  simple  and  accurate  strategy  for  proteome
profiling in cell culture systems [20]. Basically, one set of cells
are grown in a medium where some of the amino acids, usually
arginine (Arg) as well as lysine (Lys), are labeled with stable
isotopes (e.g., 13C and/or 15N), while the comparative sample
is grown in medium containing unlabeled amino acids. This
approach is the most systematic way to uniformly label all the
proteins within the cell and obtain accurate protein ratios
between  two  samples.  Indeed,  variations  usually  due  to
experimental  handling  are  minimized  in  this  case  since
labeled and unlabeled cells can be mixed before subcellular
fractionation and protein extraction. For these reasons, the
method  has  gained  tremendous  popularity  and  has  been
successfully  implemented  to  study  cell  signaling  [21–24],
phosphoproteomics [25–27], and cell-secreted proteins [13,
28,29].
In this study, we implemented the SILAC strategy to
define differential protein secretion in human RPE cell line
(ARPE-19) exposed to a non-lethal dose of TNF-α. Analysis
of these proteins should bring insight into the response of RPE
cells  to  cytokines  and  eventual  implication  in  AMD
pathogenesis.
METHODS
SILAC and TNF-α treatment: ARPE-19 was purchased from
the American Type Culture Collection (ATCC; Manassas,
VA).  The  cells  were  routinely  maintained  in  Dulbecco’s
modified Eagle’s medium and Ham’s F12 medium (DMEM/
F12) containing 10% FBS (ATCC), 100 U/ml of penicillin,
100 µg/ml of streptomycin (Invitrogen, Gibco, Carlsbad, CA),
and 1 mM of sodium pyruvate (Sigma Aldrich, St. Louis,
MO). To study the effect of TNF-α on ARPE-19 secreted
proteins, we performed differential stable isotope labeling of
amino acids in cell culture and used mass spectroscopy to
measure  ratios  of  individual  secreted  proteins  in  TNF-α
treated ARPE-19 and untreated ARPE-19 cells (Figure 1).
One set of ARPE-19 cells were subcultured in Dulbecco’s
modified Eagle’s medium and Ham’s F12 medium (DMEM/
F12; Atlanta Biologicals, Lawrenceville, GA) custom-made
medium where Arg and Lys were replaced by 13C6-Arg and
15N2, 13C6-Lys. After at least 12 cell doublings (roughly four
passages), cellular proteins were uniformly labeled with these
stable isotope-containing amino acids. In parallel, the same
numbers  of  cells  were  grown  in  DMEM/F12  unlabeled
medium.  Ten  days  after  confluence,  both  labeled  and
unlabeled  cells  were  washed  6  times  with  sterile  PBS
(Invitrogen, Carlsbad, CA) before incubating them in serum-
free medium containing stable isotope-labeled amino acids for
labeled cells and regular amino acids for unlabeled cells. The
metabolically labeled cells were treated with 10 ng/ml TNF-
α  (a  nonlethal  dose),  while  unlabeled  cells  were  kept
untreated. After 24 h incubation, spent media of both treated
and untreated cells were collected, mixed at 1:1 ratio and
analyzed  as  described  below.  To  validate  the  data,  we
performed a reverse experiment in which unlabeled cells were
treated with TNF-α while labeled cells were kept untreated.
Analysis of ARPE-19-secreted proteins: Spent media from
TNF-α-treated and untreated ARPE-19 cells were collected
and filtered through 0.2 µm polyethersulfone syringe filter
(Corning Inc., Corning, NY) to remove floating cells and
debris. Filtered media from treated and untreated cells were
then mixed at 1:1 ratio (v/v) and concentrated to dryness using
centrifugal filtration (Millipore Corporation, Billerica, MA)
followed by vacuum centrifugation. The resultant residue was
then dissolved in 6 µl of Laemmli buffer containing 50 mM
DTT and further fractionated by SDS–PAGE using 10% Tris
HCl pre-cast criterion gels (Bio-Rad, Hercules, CA). The gel
was then stained with Bio-Safe Coommassie (Bio-Rad) and
each lane was excised into 36 to 43 bands. Each band was then
in-gel digested using trypsin (Promega, Madison, WI), and the
Figure  1.  Experimental  design  to  study  the  effect  of  TNF-α  on
ARPE-19 secreted proteins. ARPE-19 cells were grown in medium
where Lys and Arg were replaced by 15N, 13C6-Lys, and 13C6-Arg. In
parallel, ARPE-19 cells were cultured in medium with normal Lys
and Arg. After cells were fully labeled with heavy and light amino
acids, 10 ng/ml of TNF-α was added into each flask of labeled cells
and unlabeled cells and incubated for 24 h in serum-free medium
while the other remaining flasks were incubated in the same serum-
free medium without TNF-α. A: For the control experiment, spent
medium from labeled cells (e.g., untreated) was mixed at a 1:1 ratio
with spent medium from unlabeled cells (e.g., untreated). B: To
check the effect of TNF-α on ARPE−19 secreted proteins, we mixed
the spent medium from labeled cells (e.g., treated with TNF-α) at a
1:1 ratio with spent medium from unlabeled cells (untreated). C: To
validate the data, we performed a reverse experiment in which spent
medium of labeled cell (e.g., untreated) was mixed at a 1:1 ratio with
unlabeled cells (e.g., treated with TNF-α). Sample pairs were then
processed as described in the method for subsequent LC-MS analysis
and determination of protein ratios.
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MS/MS as described in the next section.
Preparation of microsomal fraction: After collection of spent
media, treated and untreated cells were washed with PBS,
dissociated in 0.05% trypsin-EDTA solution (Invitrogen) and
transferred into previously weighed Eppendorf tube. Cells
were pelleted by centrifugation at 300x g then washed with 2
volumes of PBS solution and 100 mM NaCl. Treated and
untreated  cells  were  then  mixed  at  1:1  ratio  (w/w)  and
resuspended in 1.5 ml of Tris-EDTA mix buffer that contained
10 mM Tris HCl pH 7.4, 1 mM EDTA, 2.5 M sucrose (Sigma
Aldrich), and 1 protease inhibitor tablet (Pierce, Rockford, IL)
per 10 ml. The cells were then mechanically lysed by passing
them 15 times through a 1 ml syringe with a 23 gauge needle.
The suspension was centrifuged for 10 min at 4000x g at 4 °C,
and the supernatant containing the microsomal fraction was
transferred  to  a  clean  1.5  ml  Eppendorf  tube  and  further
centrifuged at 13,000x g for 20 min to obtain the microsomal
pellet. The microsomal pellet was then resuspended in protein
extraction  buffer  containing  7  M  urea,2  M  thiourea,  2%
CHAPS (w/v), and 50 mM DTT. Protein concentration of each
fraction was determined by Bio-Rad protein assay (Bio-Rad).
Aliquots of 50 µg were separated on SDS–PAGE. Gel bands
were excised, digested with trypsin, and the resultant peptides
analyzed  by  liquid  chromatography  mass  spectrometry  as
described in the next section.
Nanoflow LC-MS/MS: Nano-LC tandem mass spectrometry
was performed on an LC-packing system (Dionex Ultimate
Capillary/Nano LC system, Dionex Corp., Sunnyvale, CA)
connected to an a linear trap quadrupole (LTQ) instrument
(Thermo Fisher Scientific, San Jose, CA). Each sample was
injected  via  an  auto-sampler  and  loaded  onto  a  C18  trap
column (5 μm, 300 μm i.d. x 5 mm; Dionex LC-Packings,
Sunnyvale,  CA)  and  washed  with  water  containing  0.1%
trifluoroacetic acid for 6 min at a flow rate of 10 μl/min. The
sample was subsequently separated by a C18 reverse-phase
column (3.5 μm, 100 μm x 15 cm, Agilent, Santa Clara, CA)
at a flow rate of 200 nl/min. The mobile phases consisted of
water with 0.1% formic acid (A) and 90% acetonitrile with
0.1% formic acid (B). A linear gradient from 5 to 65% of
solvent B was employed over a period of 100 min to separate
peptide mixture. Eluted peptides were introduced into the
mass spectrometer via a 10 μm silica tip (New Objective Inc.,
Ringoes, NJ) adapted to a nano-electrospray source (Thermo
Fisher Scientific Inc., Waltham, MA). The spray voltage was
set at 1.7 kV and the heated capillary at 180 °C. LTQ was
operated in the data-dependent mode in which each cycle
consisted  of  one  full-MS  survey  and  subsequently  three
sequential  pairs  of  intercalated  zoom  scans  and  MS/MS
events. The targeted ions count in the mass spectrometer trap
was 30,000 for full-MS scans, 3,000 for zoom scans, and
10,000 for MS/MS scans. Peptides were fragmented in the
linear ion trap using collision-induced dissociation with the
collision  gas  (helium)  pressure  set  at  1.3  ml  and  the
normalized collision energy value set at 35%. The zoom scan
events, of higher resolution, were used to determine the charge
state of each ion as well as the ratio of labeled to unlabeled
peptide pairs using the ZoomQuant software developed by
Halligan et al. [30].
Database search: Protein identification was performed by
searching  the  17,806  human  protein  sequences  in  the
SwissProt database (UniProtKB/Swiss-Prot release 54.6 of
December  2007)  using  Bioworks  3.3  (Thermo  Fisher
Scientific, San Jose, CA) and indexed with assumptions for
enzymatic  tryptic  hydrolysis  with  the  possibility  of  two
missed cleavages and the following modifications: 16 Da shift
for oxidized Met, 6 and 8 Da shifts for incorporation of stable
isotope labeled Arg and Lys, respectively. Stringent filtering
criteria  were  used  for  database  search  and  peptide
identifications: DeltaCn (ΔCn) > 0.1, a variable threshold of
Xcorr versus charge state (Xcorr=1.9 for z=1, Xcorr=2.5 for
z=2, and Xcorr=3.5 for z=3), peptide probability-based score
with a p value <0.001, and more than 2 different peptides per
protein. A reverse database search using the same criteria gave
a false positive rate of 0%, thus increasing confidence in
protein identification:
ZoomQuant  analysis:  For  quantitative  analysis  we  used
ZoomQuant  Software  [30].  In  this  case  proteins  were
identified using BioWorks 3.1 software that is compatible
with ZoomQuant software to generate Sequest output files and
extract zoom scans from the mass spectrometry raw data. Each
peptide was manually validated by examining zoom scans to
verify the labeled and unlabeled pairs. Identified peptides
were required to have a matched peptide partner 6 Da greater
for Arg terminating peptides, 8 Da greater for Lys containing
peptides, and other proper combinations for missed cleavage
peptides. Because manually checking zoom scan with pairs of
labeled and unlabeled peaks is itself stringent, filtration based
on the X corr was lowered in this case to increase proteome
coverage (e.g., X corr ≥ 1.8 for doubly charged ions and X corr
≥ 2.5 for triply charged ions).
Statistical analysis: To check the significance of differentially
expressed proteins in TNF-α treated cells versus non-treated
cells a t-tests for equal variances was performed using the
Sidak method [31]. Basically an average ratio was calculated
from the total scans of labeled and unlabeled peptide pairs
detected for a given protein. These averaged ratios were then
compared in the control pairs versus TNF-α treated cells and
untreated  cells  in  both  the  forward  and  reverse  SILAC
experiment. The obtained p values were then adjusted for the
three way multiple comparisons using the Sidak method.
Western blot analysis: To validate proteome profiling data,
we cultured ARPE-19 cells in 10 cm dishes (Corning Inc. Life
Sciences,  Lowell,  MA)  to  100%  confluence.  Cells  were
washed  6  times  with  PBS  to  remove  any  residual  FBS
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False Positive Rate=
(
Reverse Database Protein
Reverse + Forward Database Protein) x 100 2 xproteins, and treated with various TNF-α concentrations (0.25
to 20 ng/ml) in serum free media for 24 h. Spent media were
collected and filtered though 0.2 µm Polyethersulfone syringe
filter (Corning Inc.). To check NF-κB activation, we collected
cell pellets, washed them with PBS, and lysed with 100 µl of
RIPA (Sigma Aldrich, St. Louis, MO) buffer. Protein extracts
were  separated  by  SDS–PAGE  on  a  4  to  15%  Tris  HCl
gradient  gel  (BioRad)  under  reducing  conditions  then
transferred  to  a  nitrocellulose  membrane  (Amersham
Biosciences,  Piscataway,  NJ)  for  western  blot  analysis.
Nonspecific  binding  was  blocked  with  5%  milk  (BioRad
Laboratories  Inc.,  Hercules,  CA),  and  the  membrane  was
incubated overnight with goat polyclonal antibody against
human  C3  (Complement  Technology,  Tyler,  TX),  rabbit
polyclonal antibody against human IκB-α (Cell Signaling,
Danvers, MA) or mouse monoclonal antibody against human
vinculin (Sigma) in 2.5% milk. The next day, the membrane
was rinsed with Tris buffer containing salt and Tween (TBST)
and incubated with antigoat antibody (Jackson Lab, West
Grove, PA) for C3, and antirabbit IgG (BioRad) for IκB-α or
antimouse  antibody  (GE  Healthcare,  Buckinghamshire,
England)  for  vinculin.  All  secondary  antibodies  were
conjugated with horseradish peroxidase, and immunoblots
were  visualized  by  chemiluminescence  (Amersham
Biosciences Inc., Piscataway, NJ)
RESULTS
Effect of TNF-α on the viability of ARPE-19 cells: To ensure
minimum cell death and minimum release of intracellular
proteins  into  the  condition  medium  of  TNF-α-treated
ARPE-19 cells, we monitored cell viability after incubating
them for 24 h with different concentrations of TNF-α using
trypan blue exclusion. Figure 2 shows the percent of viable
cells  after  24  h  incubation  with  different  TNF-α
concentrations. TNF-α concentration up to 30 ng/ml produced
only a small percent of cell death (e.g., <10% compared to
untreated cells). This data are in agreement with a previous
study  where  it  has  been  shown  that  RPE  cells  are  more
resistant  to  TNF-α-induced  apoptosis  than  other  cell  type
[32].  We  have  thus  chosen  10  ng/ml  as  the  optimal
concentration  to  study  the  effect  of  TNF-α  on  ARPE-19-
secreted proteins. This concentration resulted in minimum cell
death (<5%) and detectable cell response.
Effect of TNF-α on ARPE-19-secreted proteins: One of the
advantages of using the SILAC strategy is that all cellular
proteins, including secreted proteins, are uniformly labeled
with the stable isotope-labeled amino acids (e.g., 13C6-Arg,
13C6, 15N2-Lys). Thus, in a 1:1 mixture of spent media collected
from  labeled  and  unlabeled  cells,  most  of  the  peptides
generated from cellular proteins would be detected as pairs of
labeled and unlabeled peaks, while peptides from residual
bovine  serum  proteins  and  contaminant  proteins,  such  as
keratin, would be detected as single peaks. In this study, a total
of  221  proteins  were  identified  in  the  spent  medium  of
ARPE-19 cells, but only 146 proteins were of RPE cell origin;
these are listed in Appendix 1 with their accession number,
peptide  count,  subcellular  localization,  and  function.  The
cellular localization of these proteins as well as their function
was deduced from their annotations in the UniProt database
using the Protein Information Resources (PIR) tool. As shown
in Figure 3A, 76 (52%) of these 146 proteins were found to
be putatively secreted, 6 (4%) were of microsomal origin, 52
(36%) were of cytosolic origin, and the remaining 12 (8%)
were unassigned. While the number of identified cytosolic
proteins was high, their actual relative quantities estimated
from  spectral  count  were  low  compared  to  the  secreted
proteins  (Figure  3B).  All  proteins  in  Appendix  1  were
identified with at least two different peptides and validated by
detection of labeled and unlabeled peptide pairs. Additional
proteins that were identified by a single peptide pair in the
spent medium of ARPE-19 cells are reported in Appendix 2.
Even though each of these proteins was represented by a single
peptide  sequence,  their  identity  was  still  validated  by
detection  and  sequencing  of  both  labeled  and  unlabeled
peptide pair. Detection of only one representative peptide for
each of these proteins suggests that they might be present in
very low abundance in ARPE-19 spent medium.
Zoom scan spectra of labeled and unlabeled peptide pairs
were used to determine secreted protein ratios in TNF-α-
treated cells versus untreated cells. Figure 4 shows example
spectra of labeled and unlabeled peptide pairs of complement
C3 and syndecan-4 whose secretion was significantly altered
by TNF-α treatment. This differential secretion was clearly
Figure 2. Cell viability in function of increased TNF-α concentration.
Both viable and dead cells were counted using a hemocytometer. A
percent of viable cells to the total cells was then calculated for each
culture flask. Error bars represent standard deviations obtained from
triplicate experiment for each dose of TNF-α used. To assess the
number of cell death in the control group we have chosen not to
normalize the values to 0 ng/ml of TNF-α.
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thus validating the data. Among the 146 proteins reported in
Appendix  1,  only  6  were  found  to  be  altered  in  their
concentrations after TNF-α treatment (Figure 5). Trans-golgi
network  protein-2  (TGON2)  was  the  only  protein  whose
secretion was decreased (by a factor of 2±0.01) in TNF-α
treated cells versus untreated cells while the other 5 proteins,
complement  C3,  fibronectin,  sulfhydryl  oxidase  1,
plasminogen  activator  inhibitor  1  and  syndercan-4  were
increased by a factor of 2.03±0.42, 1.70±0.12, 2.04±0.26,
1.92±0.16, 4.35±0.54, respectively.
Because of the importance of the complement pathway
in AMD, secretion of C3 was further investigated in ARPE-19
cells treated with different doses of TNF-α. Vinculin, whose
abundance remained unchanged between TNF-α treated and
untreated  cells,  was  used  as  a  loading  control  for  data
normalization while IκB-α degradation was used to monitor
Figure 3. Cellular localization of proteins identified in spent medium
of ARPE-19 cells. Panel A shows a pie chart depicting the subcellular
distribution  of  the  proteins  identified  in  the  spent  medium  of
ARPE-19 cells. Panel B shows a bar graph plot representing the
abundance of each class of proteins based on the spectral count of
the total peptides detected. Other class of proteins with no known
subcellular localization and no known function was annotated as (N/
A) meaning not assigned.
the TNF-α induced NF-κB pathway. As shown in Figure 6,
the  secretion  of  C3  was  increased  with  TNF-α  in  dose
dependant  manner  while  I-κB  significantly  decreased,
indicating activation of the NF-κB pathway. This experiment
was  repeated  three  times,  yielding  same  trend  of  C3
expression as a function of TNF-α concentration.
DISCUSSION
Human ARPE-19 cells secret a variety of proteins that are
involved in regulation and maintenance of the extracellular
matrix,  complement  pathway,  as  well  as  immune  and
inflammatory responses. Only six proteins among the total
identified proteins in ARPE-19 condition medium were found
altered in their quantities following 24 h treatment with TNF-
α. This response indicates that ARPE-19 cells possess a cell
surface  receptor  for  TNF-α  that  acts  on  specific  gene
expression  via  activation  of  the  NF-κB  pathway  [19,33].
Indeed, this pathway was further confirmed by the observation
Figure 4. Zoom scan mass spectra of labeled and unlabeled peptide
pairs detected for complement C3 and syndecan-4 proteins. Panels A
and D show the mass spectra and the relative intensity of labeled and
unlabeled peptide pairs detected for complement C3 (A) and for
syndecan-4 (D) in TNF-α-treated ARPE-19 cells versus untreated
cells. In this case labeled cells were treated with TNF-α (+TNF-α)
while unlabeled cells remained untreated (-TNF-α). Panels B and E
show the mass spectra obtained for these same set of peptides in the
reverse experiment where unlabeled cells were treated with TNF-α
(+TNF-α) while labeled cells remained untreated (-TNF-α). Panel C
shows the tandem mass spectrum and the fragment ions obtained for
the  doubly-charged  ion  m/z=645.2  and  confirming  the  peptide
sequence [SGSDEVQVGQQR] of complement C3 protein. Panel F
shows the tandem mass spectrum and the fragment ions obtained for
the  doubly-charged  ions  m/z=579.3  and  confirming  the  peptide
sequence [AGSGSQVPTEPK] of syndecan-4 protein.
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in the activation and nuclear translocation of the transcription
factor  NF-κB  [34].  The  promoter  regions  of  the  genes
encoding  for  complement  C3,  plasminogen  activator
inhibitor, and syndercan-4 have a binding site for NF-κB as
judged from the literature and as determined by TFSEARCH
algorithm using 1,000 bp downstream of the promoter region.
Therefore,  these  genes  are  targets  for  response  to  TNF-α
treatment. Interestingly, the three other proteins altered by
TNF-α (e.g., TGON2, fibronectin, and sulfhydryl oxidase 1)
do not have any known binding site for NF-κB in the promoter
region  of  their  corresponding  genes  indicating  that  the
regulation  of  these  proteins  by  TNF-α  may  occur  via
alternative  pathways  or  involves  intermediate  proteins.
Previous  studies  have  shown  that  TNF-α  also  induces
secretion  of  a  variety  of  chemokines  (e.g.,  interleukin-8,
growth-regulated  protein-GRO,  MCP-1),  and  cytokines
(endothelin-1) in RPE cells [35–37]. Most of these studies
used  an  immunoassay  based  assay  or  mRNA  expression
assays that amplify the signal of these molecules and facilitate
their detection. In the present study, we were not able to detect
these components using our proteomic approach. This is most
likely due to their inherent limited amount and their short half
life.  Additionally,  these  proteins  are  generally  of  low
Figure 5. Bar graph for the 6 proteins whose secretion was found
differentially altered in TNF-α-treated ARPE-19 cells. Blue bars
indicate  ratios  in  control  versus  control  cells  (both  labeled  and
unlabeled cells were untreated). Purple bars indicate ratios in TNF-
α-treated cells versus untreated cells and in this case SILAC labeled
cells  were  treated  with  TNF-α  while  unlabeled  cells  were  kept
untreated. Yellow bars indicate ratios in TNF-α-treated cells versus
untreated cells and in this case unlabeled cells were treated with TNF-
α while SILAC-labeled cells were kept untreated. Numbers inside of
bars represent the total MS scans of labeled and unlabeled peptide
pairs detected for each protein. The error bars represent the standard
deviation between ratios of these individual scans. The p-values were
obtained using three pair-wise t-tests (Sidak method) where all ratios
for a given protein in control versus control were compared to ratios
obtained in TNF-α treated versus untreated cells in both the reverse
and forward experiments and these values are as follow (* represents
p-value  less  than  1.00E-05,  and  **  represents  p-value  less  than
0.001).
molecular mass  (<10 kDa) and may generate only few tryptic
peptides to be detected by mass spectrometry. This shows the
limitation of the proteomic approach in detecting this class of
proteins  and  prompt  for  additional  strategies  to  increase
proteome coverage in the future. Nevertheless, proteomics
studies allow simultaneous detection and quantification of
several proteins that otherwise would have been overlooked
in hypothesis-driven studies. Using a proteomics approach,
we  identified  additional  proteins  whose  secretion  from
ARPE-19 cells was influenced by TNF-α.
Complement  C3:  The  secretion  of  this  protein  was
significantly induced by TNF-α in ARPE-19 cells. This result
is in agreement with previous studies where it has been shown
that cytokines regulate C3 production in different cell types
including human intestinal epithelial cell line, Caco-2 [38] as
well as rat glomerular endothelial cells [39]. The production
of C3 in interleukin-1-treated intestinal cells was abolished by
NF-κB inhibitors [38], indicating that C3 is a target gene for
NF-κB transcription factor. It is most likely that a similar
pathway is involved in TNF-α-treated ARPE-19. However, to
Figure  6.  Effect  of  increasing  concentrations  of  TNF-α  on  the
secretion of Complement C3 by ARPE-19 cells. Cells were treated
with increasing concentrations of TNF-α ranging from 0 to 20 ng/ml
for 24 h in serum-free media. Spent media were collected, and the
levels of each protein were evaluated by western blot analysis. Panel
A shows western blot against complement C3; both C3-α and C3-β
subunits are detected. Panel B shows western blot against cytosolic
IκB-α revealing activation of NF-κB signaling pathway. C: western
blot against vinculin, a housekeeping protein whose level remained
unchanged following TNF-α treatment. Panel D shows bar graphs of
the relative expression of complement C3 to vinculin expression in
function of different TNF-α concentration. Standard deviations were
obtained from 3 replicate experiments with p-values <0.05.
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2297the best of our knowledge, this is the first time that TNF-α has
been shown to induce C3 secretion in human RPE cells. Local
secretion  of  C3  by  RPE  cells  could  be  detrimental  in
individuals carrying Y402H CFH variant since CFH is the
physiologic inhibitor of C3 activation and protect cells from
autologous injuries by complement C3 [40]. Additionally, it
has been shown that monocytes, which are a major source of
TNF-α, are attracted by sub-RPE deposits [41]. Therefore, in
individuals with compromised CFH activity due to the Y402H
mutation,  this  could  generate  a  positive-feedback  loop
whereby the newly attracted mononcytes generate a chronic
exposure of RPE cells to cytokines. In turn, this leads to
increased secretion of C3 by these cells, leading to progressive
immune  complex  deposition  and  autologous  complement-
mediated RPE injury. This hypothesis remains however to be
verified in a model system using primary RPE cells with
mutated and wild type CFH.
Fibronectin and syndecan-4: Secretion of fibronectin and
syndecan-4  was  significantly  induced  in  TNF-α-treated
ARPE-19  cells.  Syndecan-4,  especially,  was  threefold  to
fivefold more abundant in the spent medium of TNF-α-treated
cells versus untreated cells. These two proteins are major
constituents of the extracellular matrix (ECM) and play a
crucial  role  in  cell  adhesion  and  connectivity.  While
fibronectin is an extracellular protein that adheres to the cell
surface to maintain their integrity and shape, syndecan-4 is a
single  pass  transmembrane  protein  composed  of  an
extracellular  domain  “ectodomain”  bearing  four  heparan
sulfate  chains,  a  transmembrane  domain,  and  a  short  C-
terminal cytoplasmic domain.
Figure 7. Sequence and cellular domains of human syndecan 4. The
sequence from amino acid 1 to 18 represents the signal peptide and
is usually cleaved out in the endoplasmic reticulum before the protein
is trafficked to the cell surface. Sequence from 19 to 45 represents
the extracellular domain of the protein. Sequence from 146 to 170
represents the transmembrane domain and the sequence from 171 to
198 represents the C-terminal cytoplasmic domain. Gray highlights
tryptic peptides that were detected and identified by LC-MS/MS
analysis.  Note  that  all  the  detected  peptides  belonged  to  the
extracellular domain of the protein suggesting that syndecan 4 sheds
its ectodomain into the condition medium in response to TNF-α
treatment.
Even though treatment of ARPE-19 with TNF-α resulted
in a significant increase of fibronectin secretion neither the
literature nor software prediction support the involvement of
the NF-κB pathway in this process, suggesting that this protein
might  be  indirectly  upregulated.  Indeed,  fibronectin  was
identified in SDS–PAGE around 100 to 250 kDa indicating
that  the  protein  was  fragmented  [42].  Upregulation  of
fibronectin fragments might be due to proteases involved in
extracellular matrix degradation such as the serine protease
HtrA1 [41]. Interestingly, mutation in the promoter region of
the  gene  encoding  for  HTrA1  was  recently  found  to  be
strongly  associated  with  AMD  pathology  [9–11].
Nevertheless, the exact mechanism by which this single point
mutation leads to drusen formation and macular degeneration
remains to be further investigated. Although the molecular
mass of syndecan-4 core protein is around 21 kDa, this protein
was detected at around 250 kDa in our SDS–PAGE. This
abnormal SDS–PAGE migration is most probably due to the
O-linked  glycosaminglycan  chains.  This  hypothesis  is  in
agreement with previous studies where it has been shown that
intact syndecan migrates at higher molecular mass in the gel
than does heparinase-treated syndecan [43]. All the peptides
identifying  this  protein  in  our  study  belonged  to  the
ectodomain  sequence  (Figure  7)  suggesting  that  the  N-
terminal part of the protein is shed into the spent medium of
TNF-α treated ARPE-19 cells. Previous study has shown that
TNF-α  induces  the  overall  expression  of  syndecan-4  in
endothelial cells via NF-κB activation [44]. Other studies have
shown  that  syndecan-4  shedding  is  mediated  by  matrix
metalloproteinase-9  (MMP9)  and  is  dependent  of  NF-κB
signaling [45]. In our proteomic profiling data we did detect
2  peptides  for  MMP9  and  these  were  found  to  be  more
abundant  in  TNF-α-treated  than  untreated  cells  (data  not
shown). Unfortunately, due to the inherent low amount of this
protein in the spent medium of ARPE-19, we were not able to
detect these same peptides in our reverse experiment. What
remains to be examined is whether the increased amount of
syndecan-4  seen  in  the  spent  medium  of  TNF-α-treated
ARPE-19 cells was due to induction of its expression via NF-
κB activation or to the increased shedding of its ectodomain.
In either case, shedding of this from the surface of ARPE-19
cells exposed to TNF-α could be a protective mechanism
against  TNF-α  cytotoxicity,  and  this  may  explain  the
resistance of these cells to TNF-α-induced apoptosis [32].
Indeed, it has been documented that the TNF-α signaling
pathway synergizes with the binding of matricellular protein
CCN1/CYR61  to  syndecan-4  ectodomain  and  triggers  a
cascade  leading  to  apoptosis  [46].  Nevertheless,  the
contribution of this shedding to AMD pathogenesis remains
to  be  carefully  examined  even  though  some  studies
demonstrated that drusen contained some glycosaminoglycan
and heparan sulfate-conjugated proteoglycans [47,48]. Also,
at present it is uncertain whether CFH, an important factor in
AMD pathology, binds to heparan sulfate of syndecans and
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to increased complement C3 secretion. More studies on the
interactions between cell surface proteoglycan and CFH (both
the Y402H variant and the wild type) are needed.
Plasminogen activator inhibitor-1: Based on the spectral
count of total peptides generated per protein, plasminogen
activator inhibitor-1 (PAI-1) appears as one of the highly
abundant proteins in the spent medium of ARPE-19 cells (29
peptides and 1474 spectral count were detected for this protein
even under basal conditions). The secretion of PAI-1 was
further increased by twofold in TNF-α-treated ARPE-19 cells
versus untreated cells. Previous studies have shown that TNF-
α readily induces PAI-1 in different cell types [49–52]. PAI-1
is a physiologic inhibitor of plasminogen activator and plays
an important role in the regulation of the extracellular matrix.
Its expression is increased in several fibrotic diseases and
regulated by various cytokines, growth factors, and chemical/
physical  agents  [53].  RPE  cells  secrete  both  urokinase
plasminogen activator and its inhibitor PAI-1 [54] and the
balance between these two components likely plays a crucial
role in maintaining the extracellular environment of RPE cells
including regulation of angiogenesis [55–58]. Interestingly,
PAI-1 was found to be more abundant in the serum of patients
with early or advanced AMD than of healthy individuals,
suggesting  its  potential  implication  in  AMD  pathogenesis
[59].
Sulfhydryl oxidase 1: A protein also known as quiescin
Q6  (QSOX),  sulfhydryl  oxidase  1  has  2  known  isoforms
generated by alternative splicing. Isoform 1, a single pass
membrane protein, can be found in the endoplasmic reticulum
and Golgi apparatus while isoform 2, missing the C-terminal
domain of isoform 1, is mainly found in the extracellular space
[60]. All the 17 peptides identified for this protein in our study
belonged to isoform 2, consistent with a secreted form. In
other words, we did not detect any peptide sequence belonging
to the C-terminal domain of isoform 1. QSOX protein utilizes
a thioredoxin domain and a small flavin adenine dinucleotide
Figure 8. Effect of TNF-α on the subcellular distribution of the trans-
golgi network protein-2. Trans-golgi network protein-2 was found
to decrease in the extracellular space and increase in the microsomal
fraction in TNF-α-treated ARPE-19 cells (dark bars) when compared
to untreated ARPE-19 cells (clear bars). This strongly suggests that
TNF-α  influences  trans-golgi  network  protein-2  trafficking  in
ARPE-19 cells.
(FAD)-binding domain to form disulfide bonds in proteins
and  peptides  especially  in  proteins  destined  for  secretion
[60]. QSOX is typically found in the cell along the secretory
machinery and in the extracellular space. However, little is
known about the secreted form and its significance. Whether
this secreted form has a role in disulfide bond formation of
proteins in the extracellular space or is merely carried along
with proteins during their secretion remain to be determined.
Nevertheless and to the best of our knowledge, this is the first
demonstration  that  TNF-α  induces  secretion  of  QSOX  in
human RPE cells despite the lack of a binding site for activated
NF-κB promoter region of its gene. It is believed that this
protein may play a crucial role in ECM remodeling [61] which
might be relevant in diseases involving ECM deposition such
as AMD, Alzheimer and fibrosis.
Trans-golgi network protein 2: TGON2 was the only
protein that was found to be decreased in the spent medium
of  TNF-α-treated  versus  untreated  ARPE-19  cells.  While
TGON2 was decreased in the extracellular space of treated
cells, its amount was actually increased in the microsomal
fraction of this same set of cells (Figure 8), indicating that the
changes  were  due  to  retention  of  this  protein  rather  than
inhibition of its expression. Indeed, TGON2 is involved in
regulating  membrane  traffic  to  and  from  the  trans-Golgi
network.  RPE  cells  express  both  TNF  receptor-associated
factor-1 and 2 (TRAF-1 and TRAF-2) at their surface [33].
The decreased amount of TGON2 at the surface of TNF-α-
treated cells could be associated with the internalization of
TNF-α/ TNF-α receptor (TNFR) complex to modulate TNF-
signaling [62,63]. Indeed, it has been shown that TNFR can
be localized both at the cell surface and to the Golgi apparatus
of endothelial cells, and that TNF-α binding modulates its
trafficking [64].
Overall this study showed that TNF-α modulate the RPE
secretion of a variety of proteins that play a major role in
extracellular matrix remodeling, complement network and
angiogenesis which might be relevant to AMD pathogenesis.
Although preliminary, this study demonstrated that TNF-α
induced secretion of specific proteins in ARPE19 cells. Even
though these cells are not an ideal RPE model in respect to
primary  cultures,  they  were  used  as  proof  of  principle  to
demonstrate that several secreted proteins can be qualitatively
and  quantitatively  monitored  in  TNF-α-treated  versus
untreated cells. These proteins set may serve as a catalog for
future targeted studies that use human primary RPE cells or
human retinal cross-sections.
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2302Appendix 1. List of proteins found in the condition media of ARPE-19 cell
cultures
Serum free condition media were collected from 24 h
ARPE-19 cell cultures. The protein content in these media
were concentrated and separated by SDS–PAGE. Gel bands
where excised, digested with trypsin and the resulting peptides
analyzed by LC-MS/MS as described in the method. UniProt
ID  column  shows  accession  number  for  each  identified
protein. Peptide count column shows the number of tryptic
peptides detected and identified for each protein. The last
column indicates the subcellular localization of each protein.
Each of these proteins were identified by at least two peptides
and  validated  by  detection  of  both  labeled  and  unlabeled
peptide pairs. To access the data, click or select the words
“Appendix 1.” This will initiate the download of a compressed
(pdf) archive that contains the file.
Appendix 2. Additional proteins identified by a single peptide pair in the
spent medium of ARPE-19 cells
Additional  proteins  detected  in  the  spent  media  of
ARPE-19 cell cultures were represented by a single tryptic
peptide. The identity of this single peptide was validated by
the  presence  of  its  labeled  homolog  peptide.  UniProt  ID
column  indicates  the  accession  number  of  each  of  these
proteins.  Peptide  count  column  indicates  the  number  of
peptides identified for each of these proteins. The Scan count
column  indicates  the  number  of  times  this  peptide  was
detected and analyzed by the mass spectrometer. The higher
the number the more abundant is the peptide. The last column
indicates the subcellular location of each of these proteins. To
access the data, click or select the words “Appendix 2.” This
will initiate the download of a compressed (pdf) archive that
contains the file.
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